Clinical trialNCT06890598RecruitingPhase 3Interventional

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

SponsorEli Lilly and CompanyEnrollment700Carcinoma, Non-Small-Cell Lung

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The main purpose of this study is to assess if olomorasib in combination with pembrolizumab is more effective than the pembrolizumab and placebo combination in part A in participants with resected KRAS G12C-mutant NSCLC and to assess if olomorasib in combination with durvalumab is more effective than the durvalumab and placebo combination in part B in participants with unresectable KRAS G12C-mutant non-small cell lung cancer. The study may last up to 3 years for each participant.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
Eli Lilly and Company
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

370 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Australia

Icon Cancer Centre Wesley
Auchenflower, Australia
Adam Stirling
Recruiting
Sunshine Coast University Hospital
Birtinya, Australia
Bryan Chan
Recruiting
Austin Health
Heidelberg, Australia
Sagun Parakh
Recruiting
Icon Cancer Centre - Kurralta Park
Kurralta Park, Australia
Dainik Patel
Recruiting
Tamworth Hospital
North Tamworth, Australia
Sunil Rai
Recruiting
Sir Charles Gairdner Hospital
Perth, Australia
samantha bowyer
Recruiting
Goulburn Valley Health
Shepparton, Australia
Myron Klevansky
Recruiting
Latrobe Regional Health
Traralgon, Australia
Nguyen Chau
Recruiting

Austria

Medizinische Universität Graz
Graz, Austria
Gudrun Absenger
Recruiting
Ordensklinikum Linz Gmbh Elisabethinen
Linz, Austria
Michael Schumacher
Recruiting
Klinik Floridsdorf
Vienna, Austria
Maximilian Hochmair
Recruiting

Belgium

Chirec - Site Delta
Auderghem, Belgium
Christophe Compère
Recruiting
Antwerp University Hospital
Edegem, Belgium
Jo Raskin
Recruiting
Uz Leuven
Leuven, Belgium
christophe Dooms
Recruiting
Az Delta Vzw
Roeselare, Belgium
Ingel Demedts
Recruiting

Brazil

Fundação Pio Xii - Hospital de Câncer de Barretos
Barretos, Brazil
Dayana Mendes Ribeiro
Recruiting
Oncocentro de Minas Gerais
Belo Horizonte, Brazil
Flavia Duarte
Recruiting
Cto - Centro de Tratamento Oncológico
Belém, Brazil
Bruno Fernandes
Recruiting
Hospital Tacchini
Bento Gonçalves, Brazil
ANDRE REIRIZ
Recruiting
Centro de Pesquisa Sao Lucas
Campinas, Brazil
Rafael Carmo
Recruiting
Centro de Pesquisa Clínica Do Instituto Do Câncer Do Ceará
Fortaleza, Brazil
Fabio Chaves
Recruiting
Hospital de Cancer de Londrina
Londrina, Brazil
Mariana Piovesana
Recruiting
Liga Norte Riograndense Contra O Câncer
Natal, Brazil
Sulene Oliveira
Recruiting
Hospital São Lucas Da Pucrs
Porto Alegre, Brazil
Ana Caroline Gelatti
Recruiting
Centro de Tratamento de Tumores Botafogo Para Oncoclinicas Rio de Janeiro Sa
Rio de Janeiro, Brazil
Tatiane Montella
Recruiting
Instituto D'Or Pesquisa E Ensino
Rio de Janeiro, Brazil
Clarissa Serodio da Rocha Baldotto
Recruiting
Centro Paulista de Oncologia Clínica
São Paulo, Brazil
William Nassib William Junior
Recruiting
Hospital Santa Catarina - Paulista
São Paulo, Brazil
Gregorio Soares
Recruiting
Hospital Sírio Libanês
São Paulo, Brazil
Guilherme Harada
Recruiting
Icesp - Instituto Do Câncer Do Estado de São Paulo
São Paulo, Brazil
Gilberto Castro
Recruiting
Instituto D'Or de Pesquisa E Ensino (idor)
São Paulo, Brazil
Milena Perez Mak
Recruiting

Chile

K2 Oncology
Providencia, Chile
pablo Rodriguez Monarca
Not, yet, recruiting
Bradfordhill
Santiago, Chile
Carlos Rojas
Not, yet, recruiting
Centro de Oncología de Precisión
Santiago, Chile
Pamela Salman
Not, yet, recruiting
Falp
Santiago, Chile
Rodrigo Uribe
Not, yet, recruiting

China

Anyang Cancer Hospital
Anyang, China
Yaowen Zhang
Recruiting
Beijing Cancer Hospital
Beijing, China
Shi Yan
Recruiting
Cancer Hospital Chinese Academy of Medical Science
Beijing, China
Nan Bi
Recruiting
China-Japan Friendship Hospital
Beijing, China
Guangying Zhu
Recruiting
Peking University People'S Hospital
Beijing, China
Fan Yang
Recruiting

330 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Durvalumab →OlomorasibPembrolizumab →Placebo

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 27 Mar 2025
Primary completion: 31 May 2029
Completion: 29 Feb 2032
Last update posted: 7 Aug 2026
Registered enrollment: 700
Registry id: NCT06890598

Cross-registrations

EU-CTR / CTIS (EudraCT)2024-512302-25-00

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.